Clinical Trial: NCT06184867
Choices About Genetic Testing And Learning Your Risk With Smart Technology
Status:
COMPLETEDPhase:
Not Applicable| Lead Sponsor: | Rutgers, The State University of New Jersey |
| Information Provided By: | Rutgers, The State University of New Jersey |
| Last Update Posted: | 2026-03-06 |
Study Overview
Brief Summary
This study seeks to enhance genetic education and increase the uptake of genetic testing for hereditary cancer risk among cancer survivors. The study will focus on the feasibility and acceptability of a digital intervention designed to improve cancer genomic care.
The study objectives are to:
- Finalize the development and optimize the usability of the CATALYST digital intervention (also known as the relational assistant [RA]).
- Evaluate the feasibility and acceptability of a streamlined cancer genomic care delivery model for cancer survivors. Participants will be randomized to one of two study arms: the RA intervention arm or the enhanced usual care (EUC) arm.
- Assess the uptake of genetic counseling (GC) and genetic testing (GT) and conduct a process evaluation to identify barriers and facilitators to GC, GT, and engagement with the CATALYST intervention and the RA.
Official Title
Choices About Genetic Testing And Learning Your Risk With Smart Technology
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreas Cancer, Colorectal Cancer, Endometrial Cancer, Prostate Cancer
Intervention / Treatment
- Behavioral: Relational Agent (RA)
- Behavioral: Enhanced Usual Care (EUC)
Other Study ID Numbers
- 132307
- Pro2023000964
Start Date (Actual)
2023-09-26
Primary Completion Date (Actual)
2025-06-26
Study Completion Date (Actual)
2025-06-26
Enrollment (Actual)
50
Study Type
Interventional
Phase
Not Applicable
| Lead Sponsor: | Rutgers, The State University of New Jersey |
| Information Provided By: | Rutgers, The State University of New Jersey |
| Last Update Posted: | 2026-03-06 |
Study Overview
Brief Summary
This study seeks to enhance genetic education and increase the uptake of genetic testing for hereditary cancer risk among cancer survivors. The study will focus on the feasibility and acceptability of a digital intervention designed to improve cancer genomic care.
The study objectives are to:
- Finalize the development and optimize the usability of the CATALYST digital intervention (also known as the relational assistant [RA]).
- Evaluate the feasibility and acceptability of a streamlined cancer genomic care delivery model for cancer survivors. Participants will be randomized to one of two study arms: the RA intervention arm or the enhanced usual care (EUC) arm.
- Assess the uptake of genetic counseling (GC) and genetic testing (GT) and conduct a process evaluation to identify barriers and facilitators to GC, GT, and engagement with the CATALYST intervention and the RA.
Official Title
Choices About Genetic Testing And Learning Your Risk With Smart Technology
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreas Cancer, Colorectal Cancer, Endometrial Cancer, Prostate Cancer
Intervention / Treatment
- Behavioral: Relational Agent (RA)
- Behavioral: Enhanced Usual Care (EUC)
Other Study ID Numbers
- 132307
- Pro2023000964
Start Date (Actual)
2023-09-26
Primary Completion Date (Actual)
2025-06-26
Study Completion Date (Actual)
2025-06-26
Enrollment (Actual)
50
Study Type
Interventional
Phase
Not Applicable